NYSE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Protalix Biotherapeutics, Inc. PLX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$52.7M
▼ 1.2% vs FY2024
EPS · FY25
$-0.08
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-14.4%
Net margin · FY25
-12.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 52.7M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 13 cents on every revenue dollar this year.
Per share
USD -0.08
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-14.4%
Return on equity, FY2025
ROE
Operating margin-10.4%
Net margin-12.5%
Return on assets-8.5%
Each USD of equity lost 14 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−3.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.5%
−3.5%
+28.3%
+14.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years+131.3%
Change, 10 years—
The share count grew 131% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 82.3M
total assets, end of FY2025
Total assetsUSD 82.3M
EquityUSD 48.2M
CashUSD 14.7M
Current ratio2.51×
Equity funds 59% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.08
0.04
0.09
−0.31
−0.62
−0.22
−1.23
−1.80
−6.37
−0.29
0.61
−0.32
−0.30
−0.13
−0.43
−0.36
0.41
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−14.4
7.6
72.5
·
·
·
·
·
·
−6411.6
·
·
·
·
·
−1271.8
−197.9
Shares out B
0.08
0.08
0.07
0.05
0.05
0.03
0.01
0.01
0.14
0.12
0.10
0.09
0.09
0.09
0.09
0.08
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 2 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed